Psychedelic Drug Market
Psychedelic Drug Market Study by Depression, Post-Traumatic Stress, Substance Abuse, Obsessive Compulsive, Alzheimer Dementia, Cluster Headaches, Obesity, and Anxiety from 2024 to 2034
Analysis of Psychedelic Drug Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Psychedelic Drug Market Outlook (2024 to 2034)
The global psychedelic drug market is expected to reach a valuation of US$ 603.1 million in 2024. Projected to expand at a CAGR of 7%, worldwide sales of psychedelic drugs are expected to reach US$ 1.18 billion by the end of 2034.
Psychedelic drugs are categorized as Schedule I drugs. Historically, these drugs have been seen only to have a high potential for abuse treatment. Rising awareness regarding mental health disorders and illness is resulting in increased adoption of treatment measures for psychological ailments by the general population across the world. This is being supported by numerous awareness campaigns and initiatives by various organizations.
- Introduction of Jannsen’s Spravato, an esketamine nasal spray for the treatment of resistant depression, has led to the breakthrough scenario of the application of alternative drugs for specific indications. This has aided the demand for synthetic psychedelic drugs with growing clinical studies, suggesting the efficacy of psychedelic drugs as medicinal compounds. However, safety and monitoring of the effects of psychedelic drugs after administration still pose a concern, but the future outlook presents an opportunity for growth.
- The Johns Hopkins Center for Psychedelic and Consciousness Research is investing heavily in the development of innovative treatments for mental illnesses using psilocybin.
- In 2018, the United States Food and Drug Administration approved Epidolex, the first drug comprised of an active ingredient derived from marijuana. This oral solution is used for the treatment of severe forms of epilepsy.
The global market will offer several opportunistic openings with the expanding research & development pipeline.
- The North American psychedelic drug market size is projected to reach US$ 288.3 million by 2034.
- East Asia is estimated to capture 22.4% of the global psychedelic drug market share in 2024.
| Report Attribute | Detail |
|---|---|
| Psychedelic Drug Market Size (2024E) | US$ 603.1 Million |
| Forecasted Market Value (2034F) | US$ 1.18 Billion |
| Global Market Growth Rate (2024 to 2034) | 7% CAGR |
| South Korea Market Value (2034F) | US$ 63.3 Million |
| Psilocybin Demand Growth Rate (2024 to 2034) | 7% CAGR |
| Key Companies Profiled | Herbalife Nutrition; Havn Life; Revive Therapeutics; Amway; Jazz Pharmaceuticals; NeonMind BioSciences; Nature's Bounty Co.; NutraScience Labs; Cybin Corp.; NRx Pharmaceuticals Inc.; Seelos Therapeutics; Pfizer Inc.; Numinus; Mind Medicine; PharmaTher Holdings Ltd; GlaxoSmithKline Plc.; NOW Health Group. |
Don't Need a Global Report?
save 40%! on Country & Region specific reports
How are R&D Efforts Increasing Use of Psychedelics?
“Rising Prevalence of Mental Disorders Boosting Sales of Depression Drugs Such As Psychedelics”
Psychedelics are gaining popularity in the field of mental healing and treatment practices. Several scientists and researchers are focusing on investigating the therapeutic features of psychedelic drugs. The main focus of this research is to obtain healing solutions for depression and mental illness. Thus, the efforts made on R&D are emerging as notable psychedelic drug market trends.
- The report 'Duke Researchers Probe the Magic of Psychedelics as Medicine' published by Duke University School of Medicine in 2023 says that scientists are researching the use of psychedelics in treating disorders such as depression, addiction, and post-traumatic stress disorders.
- According to the World Health Organization Report on Depressive Disorder published in March 2023, depression is a common mental disorder affecting around 5% of adults globally. As per the same source, depression can lead to suicide.
The above-mentioned statistics explain that mental disorders can be chronic and lead to serious results if not treated on time. Mental illness hampers one’s thinking, behaving, and performing daily tasks ability. Innovations in psychedelic drugs can act as a boon to patients suffering from mental illness.
What’s Restraining Demand Growth for Psychedelic Drugs?
“Strict Regulatory Policies Limiting Production of Psychedelic Drugs”
Stringent regulatory policies are the primary restraining factors associated with the submissive production of synthetic psychedelic drugs. Reforms associated with psychedelic drug laws and policies are complex and result in variable forms of enforcement across different geographical areas.
Changes in regulations for the approval of natural psychedelic drugs are expected to cause delayed launch of products. Inflexibility in regulations is a major restraint for the dissociative psychedelic drug sales growth. Apart from these problems, one of the most challenging restraints concerning regulations is the risk associated with rescheduling and drug classification in most Western countries.
- For instance, in the United States, nearly all psychedelic substances are categorized under Schedule I drugs, which makes them inaccessible for use in the medical context because they are considered to have a high proclivity for abuse.
Demand for dissociative psychedelic drugs is in a nascent space, and thus, can invite risks related to investments in a low market cap. Under federal law, types of psychedelic drugs, such as psilocybin and MDMA, are Schedule I controlled substances, subject to various criminal penalties. Researchers need to obtain approval from the Federal Drug Enforcement Administration (DEA) if they are seeking to conduct studies of Schedule I controlled substances that are not currently approved for medical use.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Start-Up Ecosystem
- MIND Foundation is a Germany-based start-up that supports psychedelic research. The foundation acts as a study partner and works with policymakers and researchers.
- Reconnect Labs, founded in 2021, is focused on the development of innovative therapies for disorders such as depression, anxiety, trauma, and neurodegenerative diseases. This company is also developing next-gen psychedelics with improved safety, efficacy, and tolerance.
Country-wise Analysis
Why is the United States Key for Psychedelic Drug Suppliers?
“Rising Importance of Psychedelic Drugs for Mental Health Treatment Coupled with Increasing FDA Approvals”
| Attribute | United States |
|---|---|
| Market Value (2024E) | US$ 64.1 Million |
| Growth Rate (2024 to 2034) | 7.4% CAGR |
| Projected Value (2034F) | US$ 131.5 Million |
The United States leads the North American market with a share of 44.5% in 2024 and is projected to continue experiencing high growth throughout the study period (2024 to 2034). Growth of the United States market is driven by the recognition of active compounds derived from psychedelic drugs by the Food and Drug Administration (FDA). The approval of Spravato (esketamine) nasal spray by the FDA is supporting the United States market growth and generating opportunities in the field of psychedelic drug production for the treatment of mental disorders.
Will Germany Be a Lucrative Market for Psychedelic Drug Manufacturers?
“Depression Prime Mental Issue in Germany”
Germany is one of the major markets for psychedelic drugs in the European region. Depression is one of the prime mental issues in European countries including Germany. People's willingness and ability to spend on mental wellness is set to generate profitable opportunities for psychedelic drug producers. This, along with approved sales of FDA-approved psychedelic drugs for medicinal indications, is expected to aid the demand growth of psychedelic drugs in the country.
How is Japan Faring in the Psychedelic Drug Business?
“Research on Developing Effective Psychedelic Medicine for Depression among Cancer Patients”
| Attribute | Japan |
|---|---|
| Market Value (2024E) | US$ 39 Million |
| Growth Rate (2024 to 2034) | 7.5% CAGR |
| Projected Value (2034F) | US$ 80.6 Million |
FDA-approved psychedelic product sales in the country are leading to increasing investments in research activities. Rising penetration of key pharmaceutical players in Japan for oncology-associated treatment and ketamine psychedelic drugs is expected to open the gateway to psychedelic drug development for medicinal purposes.
- According to the National Cancer Institute, psilocybin, a substance derived from mushroom 'psilocybe mexicana', is being studied for the treatment of anxiety or depression in cancer patients.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Category-wise Analysis
Which Source is Popular for Manufacturing Psychedelic Drugs?
“Synthetic Psychedelic Drugs Effective in Production and Reproduction of Compounds and Active Pharmaceutical Products”
| Attribute | Synthetic Psychedelic Drugs |
|---|---|
| Segment Value (2024E) | US$ 329.3 Million |
| Growth Rate (2024 to 2034) | 7.1% CAGR |
| Projected Value (2034F) | US$ 654.8 Million |
Synthetic psychedelic drugs are projected to hold 55.2% of the global market share by 2034. Demand for synthetic psychedelic drugs is high because of the selective production of compounds and active pharmaceutical products for the production of novel drug formulations. This is effective in terms of the reproduction of compounds after extraction.
Which Therapeutic Drug is Highly Preferred?
“Lysergic Acid Diethylamide (LSD) Widely Consumed Mental Illness Therapeutic Drug”
| Attribute | LSD |
|---|---|
| Segment Value (2024E) | US$ 145.9 Million |
| Growth Rate (2024 to 2034) | 6.2% CAGR |
| Projected Value (2034F) | US$ 265.7 Million |
Lysergic acid diethylamide (LSD) consumption is on the rise for people with depression. LSD being a semi-synthetic drug is derived from a chemical called diethylamide and a fungus called ergot. LSD stimulates the production of serotonin in the brain, which changes thoughts and mood. The easy availability and low price is another factor expected to boost LSD sales growth.
Competitive Landscape
Research and development activities, collaborations, sponsorships, fundraising, and partnerships are key growth strategies adopted by psychedelic drug manufacturing companies. By focusing on these strategies, key players in the psychedelic drug market are expanding their geographic footprints and strengthening their existing product portfolios.
- In October 2022, Numinus Wellness Inc. announced the launch of psychedelic-assisted therapy for chronic and serious medical illness disorders.
Fact.MR provides detailed information about the price points of key producers of psychedelic drugs positioned across the world, sales growth, production capacity, and speculative technological expansion, in the recently updated market report.
Key Segments of Psychedelic Drug Market Research
-
By Source :
- Natural Psychedelic Drugs
- Synthetic Psychedelic Drugs
-
By Therapeutic Drug :
- Psilocybin
- LSD
- MDMA
- DMT
- Ketamine
-
By Indication :
- Depressive Disorders
- Post-Traumatic Stress Disorders
- Substance Abuse Disorders
- Obsessive Compulsive Disorders
- Alzheimer Dementia
- Cluster Headaches
- Terminal Cancer Distress
- Anorexia and Obesity
- Personality Disorders
- Anxiety
-
By Route of Administration :
- Oral Psychedelic Drugs
- Liquid
- Capsules
- Tablets
- Injectable Psychedelic Drugs
- Intramuscular
- Subcutaneous
- Intrathecal
- Rectal Psychedelic Drugs
- Nasal Psychedelic Drugs
- Transdermal Psychedelic Drugs
- Oral Psychedelic Drugs
-
By Distribution Channel :
- Online Pharmacies
- Hospital Pharmacies
- Institutional Sales
- Retail Sales
- Retail Pharmacies
-
By Region :
- North America
- Latin America
- Western Europe
- Eastern Europe
- East Asia
- South Asia & Pacific
- Middle East & Africa
Table of Content
1. Executive Summary 2. Industry Introduction, including Taxonomy and Market Definition 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments 4. Global Market Demand Analysis 2019 to 2023 and Forecast 2024 to 2034, including Historical Analysis and Future Projections 5. Pricing Analysis 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034 6.1. Source 6.2. Indication 6.3. Therapeutic Drug 6.4. Route of Administration 6.5. Distribution Channel 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Source 7.1. Natural Psychedelic Drugs 7.2. Synthetic Psychedelic Drugs 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Indication 8.1. Depressive Disorders 8.2. Post-Traumatic Stress Disorders 8.3. Substance Abuse Disorders 8.4. Obsessive Compulsive Disorders 8.5. Alzheimer Dementia 8.6. Cluster Headaches 8.7. Terminal Cancer Distress 8.8. Anorexia and Obesity 8.9. Personality Disorders 8.10. Anxiety 9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Therapeutic Drug 9.1. Psilocybin 9.2. LSD 9.3. MDMA 9.4. DMT 9.5. Ketamine 10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Route of Administration 10.1. Oral Psychedelic Drugs 10.2. Injectable Psychedelic Drugs 10.3. Rectal Psychedelic Drugs 10.4. Nasal Psychedelic Drugs 10.5. Transdermal Psychedelic Drugs 11. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Distribution Channel 11.1. Online Pharmacies 11.2. Hospital Pharmacies 11.3. Retail Pharmacies 12. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Region 12.1. North America 12.2. Latin America 12.3. Western Europe 12.4. Eastern Europe 12.5. East Asia 12.6. South Asia & Pacific 12.7. Middle East & Africa 13. North America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 14. Latin America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 15. Western Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 16. Eastern Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 17. East Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 18. South Asia & Pacific Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 19. Middle East & Africa Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 20. Sales Forecast 2024 to 2034 by Source, Indication, Therapeutic Drug, Route of Administration, Distribution Channel, and Region for 30 Countries 21. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard 22. Company Profile 22.1. Herbalife Nutrition 22.2. Havn Life 22.3. Revive Therapeutics 22.4. Amway 22.5. Jazz Pharmaceuticals 22.6. NeonMind BioSciences 22.7. Nature's Bounty Co. 22.8. NutraScience Labs 22.9. Cybin Corp. 22.10. NRx Pharmaceuticals Inc. 22.11. Seelos Therapeutics 22.12. Pfizer Inc. 22.13. Numinus 22.14. Mind Medicine 22.15. PharmaTher Holdings Ltd 22.16. GlaxoSmithKline Plc. 22.17. NOW Health Group 23. Assumptions and Acronyms Used 24. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Market Value (US$ Mn) Analysis, by Source, 2019 to 2023
Table 02: Global Market Value (US$ Mn) Analysis, by Source, 2024 to 2034
Table 03: Global Market Value (US$ Mn) Opportunity Analysis, by Source, 2024 to 2034
Table 04: Global Market Value (US$ Mn) Analysis, by Indication, 2019 to 2023
Table 05: Global Market Value (US$ Mn) Analysis, by Indication, 2024 to 2034
Table 06: Global Market Value (US$ Mn) Opportunity Analysis, by Indication, 2024 to 2034
Table 07: Global Market Value (US$ Mn) Analysis, by Therapeutic Drug, 2019 to 2023
Table 08: Global Market Value (US$ Mn) Analysis, by Therapeutic Drug, 2024 to 2034
Table 09: Global Market Value (US$ Mn) Opportunity Analysis, by Therapeutic Drug, 2024 to 2034
Table 10: Global Market Value (US$ Mn) Analysis, by Route of Administration, 2019 to 2023
Table 11: Global Market Value (US$ Mn) Analysis, by Route of Administration, 2024 to 2034
Table 12: Global Market Value (US$ Mn) Opportunity Analysis, by Route of Administration, 2024 to 2034
Table 13: Global Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 14: Global Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 15: Global Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 16: Global Market Value (US$ Mn) Analysis, by Region, 2019 to 2023
Table 17: Global Market Value (US$ Mn) Analysis, by Region, 2024 to 2034
Table 18: Global Market Value (US$ Mn) Opportunity Analysis, by Region, 2024 to 2034
Table 19: North America Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 20: North America Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 21: North America Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 22: North America Market Value (US$ Mn) Analysis, by Source, 2019 to 2023
Table 23: North America Market Value (US$ Mn) Analysis, by Source, 2024 to 2034
Table 24: North America Market Value (US$ Mn) Opportunity Analysis, by Source, 2024 to 2034
Table 25: North America Market Value (US$ Mn) Analysis, by Indication, 2019 to 2023
Table 26: North America Market Value (US$ Mn) Analysis, by Indication, 2024 to 2034
Table 27: North America Market Value (US$ Mn) Opportunity Analysis, by Indication, 2024 to 2034
Table 28: North America Market Value (US$ Mn) Analysis, by Therapeutic Drug, 2019 to 2023
Table 29: North America Market Value (US$ Mn) Analysis, by Therapeutic Drug, 2024 to 2034
Table 30: North America Market Value (US$ Mn) Opportunity Analysis, by Therapeutic Drug, 2024 to 2034
Table 31: North America Market Value (US$ Mn) Analysis, by Route of Administration, 2019 to 2023
Table 32: North America Market Value (US$ Mn) Analysis, by Route of Administration, 2024 to 2034
Table 33: North America Market Value (US$ Mn) Opportunity Analysis, by Route of Administration, 2024 to 2034
Table 34: North America Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 35: North America Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 36: North America Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 37: Latin America Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 38: Latin America Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 39: Latin America Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 40: Latin America Market Value (US$ Mn) Analysis, by Source, 2019 to 2023
Table 41: Latin America Market Value (US$ Mn) Analysis, by Source, 2024 to 2034
Table 42: Latin America Market Value (US$ Mn) Opportunity Analysis, by Source, 2024 to 2034
Table 43: Latin America Market Value (US$ Mn) Analysis, by Indication, 2019 to 2023
Table 44: Latin America Market Value (US$ Mn) Analysis, by Indication, 2024 to 2034
Table 45: Latin America Market Value (US$ Mn) Opportunity Analysis, by Indication, 2024 to 2034
Table 46: Latin America Market Value (US$ Mn) Analysis, by Therapeutic Drug, 2019 to 2023
Table 47: Latin America Market Value (US$ Mn) Analysis, by Therapeutic Drug, 2024 to 2034
Table 48: Latin America Market Value (US$ Mn) Opportunity Analysis, by Therapeutic Drug, 2024 to 2034
Table 49: Latin America Market Value (US$ Mn) Analysis, by Route of Administration, 2019 to 2023
Table 50: Latin America Market Value (US$ Mn) Analysis, by Route of Administration, 2024 to 2034
Table 51: Latin America Market Value (US$ Mn) Opportunity Analysis, by Route of Administration, 2024 to 2034
Table 52: Latin America Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 53: Latin America Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 54: Latin America Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 55: Western Europe Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 56: Western Europe Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 57: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 58: Western Europe Market Value (US$ Mn) Analysis, by Source, 2019 to 2023
Table 59: Western Europe Market Value (US$ Mn) Analysis, by Source, 2024 to 2034
Table 60: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Source, 2024 to 2034
Table 61: Western Europe Market Value (US$ Mn) Analysis, by Indication, 2019 to 2023
Table 62: Western Europe Market Value (US$ Mn) Analysis, by Indication, 2024 to 2034
Table 63: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Indication, 2024 to 2034
Table 64: Western Europe Market Value (US$ Mn) Analysis, by Therapeutic Drug, 2019 to 2023
Table 65: Western Europe Market Value (US$ Mn) Analysis, by Therapeutic Drug, 2024 to 2034
Table 66: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Therapeutic Drug, 2024 to 2034
Table 67: Western Europe Market Value (US$ Mn) Analysis, by Route of Administration, 2019 to 2023
Table 68: Western Europe Market Value (US$ Mn) Analysis, by Route of Administration, 2024 to 2034
Table 69: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Route of Administration, 2024 to 2034
Table 70: Western Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 71: Western Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 72: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 73: Eastern Europe Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 74: Eastern Europe Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 75: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 76: Eastern Europe Market Value (US$ Mn) Analysis, by Source, 2019 to 2023
Table 77: Eastern Europe Market Value (US$ Mn) Analysis, by Source, 2024 to 2034
Table 78: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Source, 2024 to 2034
Table 79: Eastern Europe Market Value (US$ Mn) Analysis, by Indication, 2019 to 2023
Table 80: Eastern Europe Market Value (US$ Mn) Analysis, by Indication, 2024 to 2034
Table 81: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Indication, 2024 to 2034
Table 82: Eastern Europe Market Value (US$ Mn) Analysis, by Therapeutic Drug, 2019 to 2023
Table 83: Eastern Europe Market Value (US$ Mn) Analysis, by Therapeutic Drug, 2024 to 2034
Table 84: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Therapeutic Drug, 2024 to 2034
Table 85: Eastern Europe Market Value (US$ Mn) Analysis, by Route of Administration, 2019 to 2023
Table 86: Eastern Europe Market Value (US$ Mn) Analysis, by Route of Administration, 2024 to 2034
Table 87: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Route of Administration, 2024 to 2034
Table 88: Eastern Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 89: Eastern Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 90: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 91: East Asia Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 92: East Asia Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 93: East Asia Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 94: East Asia Market Value (US$ Mn) Analysis, by Source, 2019 to 2023
Table 95: East Asia Market Value (US$ Mn) Analysis, by Source, 2024 to 2034
Table 96: East Asia Market Value (US$ Mn) Opportunity Analysis, by Source, 2024 to 2034
Table 97: East Asia Market Value (US$ Mn) Analysis, by Indication, 2019 to 2023
Table 98: East Asia Market Value (US$ Mn) Analysis, by Indication, 2024 to 2034
Table 99: East Asia Market Value (US$ Mn) Opportunity Analysis, by Indication, 2024 to 2034
Table 100: East Asia Market Value (US$ Mn) Analysis, by Therapeutic Drug, 2019 to 2023
Table 101: East Asia Market Value (US$ Mn) Analysis, by Therapeutic Drug, 2024 to 2034
Table 102: East Asia Market Value (US$ Mn) Opportunity Analysis, by Therapeutic Drug, 2024 to 2034
Table 103: East Asia Market Value (US$ Mn) Analysis, by Route of Administration, 2019 to 2023
Table 104: East Asia Market Value (US$ Mn) Analysis, by Route of Administration, 2024 to 2034
Table 105: East Asia Market Value (US$ Mn) Opportunity Analysis, by Route of Administration, 2024 to 2034
Table 106: East Asia Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 107: East Asia Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 108: East Asia Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 109: South Asia & Pacific Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 110: South Asia & Pacific Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 111: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 112: South Asia & Pacific Market Value (US$ Mn) Analysis, by Source, 2019 to 2023
Table 113: South Asia & Pacific Market Value (US$ Mn) Analysis, by Source, 2024 to 2034
Table 114: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Source, 2024 to 2034
Table 115: South Asia & Pacific Market Value (US$ Mn) Analysis, by Indication, 2019 to 2023
Table 116: South Asia & Pacific Market Value (US$ Mn) Analysis, by Indication, 2024 to 2034
Table 117: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Indication, 2024 to 2034
Table 118: South Asia & Pacific Market Value (US$ Mn) Analysis, by Therapeutic Drug, 2019 to 2023
Table 119: South Asia & Pacific Market Value (US$ Mn) Analysis, by Therapeutic Drug, 2024 to 2034
Table 120: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Therapeutic Drug, 2024 to 2034
Table 121: South Asia & Pacific Market Value (US$ Mn) Analysis, by Route of Administration, 2019 to 2023
Table 122: South Asia & Pacific Market Value (US$ Mn) Analysis, by Route of Administration, 2024 to 2034
Table 123: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Route of Administration, 2024 to 2034
Table 124: South Asia & Pacific Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 125: South Asia & Pacific Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 126: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 127: MEA Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 128: MEA Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 129: MEA Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 130: MEA Market Value (US$ Mn) Analysis, by Source, 2019 to 2023
Table 131: MEA Market Value (US$ Mn) Analysis, by Source, 2024 to 2034
Table 132: MEA Market Value (US$ Mn) Opportunity Analysis, by Source, 2024 to 2034
Table 133: MEA Market Value (US$ Mn) Analysis, by Indication, 2019 to 2023
Table 134: MEA Market Value (US$ Mn) Analysis, by Indication, 2024 to 2034
Table 135: MEA Market Value (US$ Mn) Opportunity Analysis, by Indication, 2024 to 2034
Table 136: MEA Market Value (US$ Mn) Analysis, by Therapeutic Drug, 2019 to 2023
Table 137: MEA Market Value (US$ Mn) Analysis, by Therapeutic Drug, 2024 to 2034
Table 138: MEA Market Value (US$ Mn) Opportunity Analysis, by Therapeutic Drug, 2024 to 2034
Table 139: MEA Market Value (US$ Mn) Analysis, by Route of Administration, 2019 to 2023
Table 140: MEA Market Value (US$ Mn) Analysis, by Route of Administration, 2024 to 2034
Table 141: MEA Market Value (US$ Mn) Opportunity Analysis, by Route of Administration, 2024 to 2034
Table 142: MEA Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 143: MEA Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 144: MEA Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 02: Global Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 03: Global Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 04: Global Market Incremental $ Opportunity, 2024 to 2034
Figure 05: Global Market Share and BPS Analysis by Source, 2024 & 2034
Figure 06: Global Market Y-o-Y Growth Projections by Source, 2024 to 2034
Figure 07: Global Market Attractiveness Analysis by Source, 2024 to 2034
Figure 08: Global Market Share and BPS Analysis by Indication, 2024 & 2034
Figure 09: Global Market Y-o-Y Growth Projections by Indication, 2024 to 2034
Figure 10: Global Market Attractiveness Analysis by Indication, 2024 to 2034
Figure 11: Global Market Share and BPS Analysis by Therapeutic Drug, 2024 & 2034
Figure 12: Global Market Y-o-Y Growth Projections by Therapeutic Drug, 2024 to 2034
Figure 13: Global Market Attractiveness Analysis by Therapeutic Drug, 2024 to 2034
Figure 14: Global Market Share and BPS Analysis by Route of Administration, 2024 & 2034
Figure 15: Global Market Y-o-Y Growth Projections by Route of Administration, 2024 to 2034
Figure 16: Global Market Attractiveness Analysis by Route of Administration, 2024 to 2034
Figure 17: Global Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 18: Global Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 19: Global Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 20: Global Market Share and BPS Analysis by Region, 2024 & 2034
Figure 21: Global Market Y-o-Y Growth Projections by Region, 2024 to 2034
Figure 22: Global Market Attractiveness Analysis by Region, 2024 to 2034
Figure 23: North America Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 24: North America Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 25: North America Market Value Y-o-Y Growth and Forecast, 2034
Figure 26: North America Market Incremental $ Opportunity, 2024 to 2034
Figure 27: North America Market Share Analysis by Country, 2024 & 2034
Figure 28: North America Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 29: North America Market Attractiveness Analysis by Country, 2024 to 2034
Figure 30: North America Market Share and BPS Analysis by Source, 2024 & 2034
Figure 31: North America Market Y-o-Y Growth Projections by Source, 2024 to 2034
Figure 32: North America Market Attractiveness Analysis by Source, 2024 to 2034
Figure 33: North America Market Share and BPS Analysis by Indication, 2024 & 2034
Figure 34: North America Market Y-o-Y Growth Projections by Indication, 2024 to 2034
Figure 35: North America Market Attractiveness Analysis by Indication, 2024 to 2034
Figure 36: North America Market Share and BPS Analysis by Therapeutic Drug, 2024 & 2034
Figure 37: North America Market Y-o-Y Growth Projections by Therapeutic Drug, 2024 to 2034
Figure 38: North America Market Attractiveness Analysis by Therapeutic Drug, 2024 to 2034
Figure 39: North America Market Share and BPS Analysis by Route of Administration, 2024 & 2034
Figure 40: North America Market Y-o-Y Growth Projections by Route of Administration, 2024 to 2034
Figure 41: North America Market Attractiveness Analysis by Route of Administration, 2024 to 2034
Figure 42: North America Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 43: North America Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 44: North America Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 45: Latin America Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 46: Latin America Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 47: Latin America Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 48: Latin America Market Incremental $ Opportunity, 2024 to 2034
Figure 49: Latin America Market Share Analysis by Country, 2024 & 2034
Figure 50: Latin America Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 51: Latin America Market Attractiveness Analysis by Country, 2024 to 2034
Figure 52: Latin America Market Share and BPS Analysis by Source, 2024 & 2034
Figure 53: Latin America Market Y-o-Y Growth Projections by Source, 2024 to 2034
Figure 54: Latin America Market Attractiveness Analysis by Source, 2024 to 2034
Figure 55: Latin America Market Share and BPS Analysis by Indication, 2024 & 2034
Figure 56: Latin America Market Y-o-Y Growth Projections by Indication, 2024 to 2034
Figure 57: Latin America Market Attractiveness Analysis by Indication, 2024 to 2034
Figure 58: Latin America Market Share and BPS Analysis by Therapeutic Drug, 2024 & 2034
Figure 59: Latin America Market Y-o-Y Growth Projections by Therapeutic Drug, 2024 to 2034
Figure 60: Latin America Market Attractiveness Analysis by Therapeutic Drug, 2024 to 2034
Figure 61: Latin America Market Share and BPS Analysis by Route of Administration, 2024 & 2034
Figure 62: Latin America Market Y-o-Y Growth Projections by Route of Administration, 2024 to 2034
Figure 63: Latin America Market Attractiveness Analysis by Route of Administration, 2024 to 2034
Figure 64: Latin America Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 65: Latin America Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 66: Latin America Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 67: Western Europe Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 68: Western Europe Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 69: Western Europe Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 70: Western Europe Market Incremental $ Opportunity, 2024 to 2034
Figure 71: Western Europe Market Share Analysis by Country, 2024 & 2034
Figure 72: Western Europe Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 73: Western Europe Market Attractiveness Analysis by Country, 2024 to 2034
Figure 74: Western Europe Market Share and BPS Analysis by Source, 2024 & 2034
Figure 75: Western Europe Market Y-o-Y Growth Projections by Source, 2024 to 2034
Figure 76: Western Europe Market Attractiveness Analysis by Source, 2024 to 2034
Figure 77: Western Europe Market Share and BPS Analysis by Indication, 2024 & 2034
Figure 78: Western Europe Market Y-o-Y Growth Projections by Indication, 2024 to 2034
Figure 79: Western Europe Market Attractiveness Analysis by Indication, 2024 to 2034
Figure 80: Western Europe Market Share and BPS Analysis by Therapeutic Drug, 2024 & 2034
Figure 81: Western Europe Market Y-o-Y Growth Projections by Therapeutic Drug, 2024 to 2034
Figure 82: Western Europe Market Attractiveness Analysis by Therapeutic Drug, 2024 to 2034
Figure 83: Western Europe Market Share and BPS Analysis by Route of Administration, 2024 & 2034
Figure 84: Western Europe Market Y-o-Y Growth Projections by Route of Administration, 2024 to 2034
Figure 85: Western Europe Market Attractiveness Analysis by Route of Administration, 2024 to 2034
Figure 86: Western Europe Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 87: Western Europe Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 88: Western Europe Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 89: Eastern Europe Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 90: Eastern Europe Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 91: Eastern Europe Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 92: Eastern Europe Market Incremental $ Opportunity, 2024 to 2034
Figure 93: Eastern Europe Market Share Analysis by Country, 2024 & 2034
Figure 94: Eastern Europe Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 95: Eastern Europe Market Attractiveness Analysis by Country, 2024 to 2034
Figure 96: Eastern Europe Market Share and BPS Analysis by Source, 2024 & 2034
Figure 97: Eastern Europe Market Y-o-Y Growth Projections by Source, 2024 to 2034
Figure 98: Eastern Europe Market Attractiveness Analysis by Source, 2024 to 2034
Figure 99: Eastern Europe Market Share and BPS Analysis by Indication, 2024 & 2034
Figure 100: Eastern Europe Market Y-o-Y Growth Projections by Indication, 2024 to 2034
Figure 101: Eastern Europe Market Attractiveness Analysis by Indication, 2024 to 2034
Figure 102: Eastern Europe Market Share and BPS Analysis by Therapeutic Drug, 2024 & 2034
Figure 103: Eastern Europe Market Y-o-Y Growth Projections by Therapeutic Drug, 2024 to 2034
Figure 104: Eastern Europe Market Attractiveness Analysis by Therapeutic Drug, 2024 to 2034
Figure 105: Eastern Europe Market Share and BPS Analysis by Route of Administration, 2024 & 2034
Figure 106: Eastern Europe Market Y-o-Y Growth Projections by Route of Administration, 2024 to 2034
Figure 107: Eastern Europe Market Attractiveness Analysis by Route of Administration, 2024 to 2034
Figure 108: Eastern Europe Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 109: Eastern Europe Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 110: Eastern Europe Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 111: East Asia Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 112: East Asia Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 113: East Asia Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 114: East Asia Market Incremental $ Opportunity, 2024 to 2034
Figure 115: East Asia Market Share Analysis by Country, 2024 & 2034
Figure 116: East Asia Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 117: East Asia Market Attractiveness Analysis by Country, 2024 to 2034
Figure 118: East Asia Market Share and BPS Analysis by Source, 2024 & 2034
Figure 119: East Asia Market Y-o-Y Growth Projections by Source, 2024 to 2034
Figure 120: East Asia Market Attractiveness Analysis by Source, 2024 to 2034
Figure 121: East Asia Market Share and BPS Analysis by Indication, 2024 & 2034
Figure 122: East Asia Market Y-o-Y Growth Projections by Indication, 2024 to 2034
Figure 123: East Asia Market Attractiveness Analysis by Indication, 2024 to 2034
Figure 124: East Asia Market Share and BPS Analysis by Therapeutic Drug, 2024 & 2034
Figure 125: East Asia Market Y-o-Y Growth Projections by Therapeutic Drug, 2024 to 2034
Figure 126: East Asia Market Attractiveness Analysis by Therapeutic Drug, 2024 to 2034
Figure 127: East Asia Market Share and BPS Analysis by Route of Administration, 2024 & 2034
Figure 128: East Asia Market Y-o-Y Growth Projections by Route of Administration, 2024 to 2034
Figure 129: East Asia Market Attractiveness Analysis by Route of Administration, 2024 to 2034
Figure 130: East Asia Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 131: East Asia Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 132: East Asia Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 133: South Asia & Pacific Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 134: South Asia & Pacific Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 135: South Asia & Pacific Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 136: South Asia & Pacific Market Incremental $ Opportunity, 2024 to 2034
Figure 137: South Asia & Pacific Market Share Analysis by Country, 2024 & 2034
Figure 138: South Asia & Pacific Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 139: South Asia & Pacific Market Attractiveness Analysis by Country, 2024 to 2034
Figure 140: South Asia & Pacific Market Share and BPS Analysis by Source, 2024 & 2034
Figure 141: South Asia & Pacific Market Y-o-Y Growth Projections by Source, 2024 to 2034
Figure 142: South Asia & Pacific Market Attractiveness Analysis by Source, 2024 to 2034
Figure 143: South Asia & Pacific Market Share and BPS Analysis by Indication, 2024 & 2034
Figure 144: South Asia & Pacific Market Y-o-Y Growth Projections by Indication, 2024 to 2034
Figure 145: South Asia & Pacific Market Attractiveness Analysis by Indication, 2024 to 2034
Figure 146: South Asia & Pacific Market Share and BPS Analysis by Therapeutic Drug, 2024 & 2034
Figure 147: South Asia & Pacific Market Y-o-Y Growth Projections by Therapeutic Drug, 2024 to 2034
Figure 148: South Asia & Pacific Market Attractiveness Analysis by Therapeutic Drug, 2024 to 2034
Figure 149: South Asia & Pacific Market Share and BPS Analysis by Route of Administration, 2024 & 2034
Figure 150: South Asia & Pacific Market Y-o-Y Growth Projections by Route of Administration, 2024 to 2034
Figure 151: South Asia & Pacific Market Attractiveness Analysis by Route of Administration, 2024 to 2034
Figure 152: South Asia & Pacific Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 153: South Asia & Pacific Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 154: South Asia & Pacific Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 155: MEA Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 156: MEA Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 157: MEA Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 158: MEA Market Incremental $ Opportunity, 2024 to 2034
Figure 159: MEA Market Share Analysis by Country, 2024 & 2034
Figure 160: MEA Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 161: MEA Market Attractiveness Analysis by Country, 2024 to 2034
Figure 162: MEA Market Share and BPS Analysis by Source, 2024 & 2034
Figure 163: MEA Market Y-o-Y Growth Projections by Source, 2024 to 2034
Figure 164: MEA Market Attractiveness Analysis by Source, 2024 to 2034
Figure 165: MEA Market Share and BPS Analysis by Indication, 2024 & 2034
Figure 166: MEA Market Y-o-Y Growth Projections by Indication, 2024 to 2034
Figure 167: MEA Market Attractiveness Analysis by Indication, 2024 to 2034
Figure 168: MEA Market Share and BPS Analysis by Therapeutic Drug, 2024 & 2034
Figure 169: MEA Market Y-o-Y Growth Projections by Therapeutic Drug, 2024 to 2034
Figure 170: MEA Market Attractiveness Analysis by Therapeutic Drug, 2024 to 2034
Figure 171: MEA Market Share and BPS Analysis by Route of Administration, 2024 & 2034
Figure 172: MEA Market Y-o-Y Growth Projections by Route of Administration, 2024 to 2034
Figure 173: MEA Market Attractiveness Analysis by Route of Administration, 2024 to 2034
Figure 174: MEA Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 175: MEA Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 176: MEA Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
How big is the psychedelic drug market in 2024?
The global psychedelic drug market is estimated at US$ 603.1 million in 2024.
What are the sales projections for psychedelic drugs by 2034?
Worldwide sales of psychedelic drugs are forecasted to reach US$ 1.18 billion by 2034.
What is the psychedelic drug market’s predicted demand growth?
Demand for psychedelic drugs is foreseen to rise at a CAGR of 7% from 2024 to 2034.
Which type of psychedelic drug is most widely demanded?
DMT (N,N-Dimethyltryptamine) drug demand is calculated to increase at a CAGR of 7.7% through 2034.
Which region is a key consumer of psychedelic drugs?
The North American market is projected to reach US$ 288.3 million by 2034.
What is the estimated market size of psychedelic drugs in South Korea?
The South Korea market is approximated at US$ 30 million in 2024.
Who are the top producers of psychedelic drugs?
Leading market players are Numinus, Mind Medicine, PharmaTher Holdings Ltd, and GlaxoSmithKline Plc.
What is the psychedelic therapy used for?
Psychedelic drugs are mainly used in the treatment of mental illnesses.
Psychedelic Drug Market